Australia Markets closed
  • ALL ORDS

    7,266.30
    +151.80 (+2.13%)
     
  • ASX 200

    6,988.10
    +149.80 (+2.19%)
     
  • AUD/USD

    0.7038
    +0.0005 (+0.0640%)
     
  • OIL

    87.31
    +0.70 (+0.81%)
     
  • GOLD

    1,796.90
    +3.80 (+0.21%)
     
  • BTC-AUD

    52,911.09
    +1,293.95 (+2.51%)
     
  • CMC Crypto 200

    845.00
    +25.50 (+3.11%)
     
  • AUD/EUR

    0.6309
    +0.0000 (+0.00%)
     
  • AUD/NZD

    1.0690
    +0.0009 (+0.08%)
     
  • NZX 50

    11,852.15
    -198.17 (-1.64%)
     
  • NASDAQ

    14,003.11
    -169.65 (-1.20%)
     
  • FTSE

    7,554.31
    +84.53 (+1.13%)
     
  • Dow Jones

    34,160.78
    -7.31 (-0.02%)
     
  • DAX

    15,524.27
    +64.88 (+0.42%)
     
  • Hang Seng

    23,624.42
    -182.58 (-0.77%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     

Maria Teresa Hilado to Join Galderma’s Advisory Committee

·2-min read
  • Maria Teresa "Tessa" Hilado will join Galderma’s Advisory Committee on January 1, 2022

  • Formerly Executive Vice President and Chief Financial Officer at pharmaceutical company Allergan, Ms. Hilado currently sits on the boards of Campbell Soup Company, Zimmer Biomet Holdings, Inc. and Pharmaceutical Product Development, LLC

  • She will bring to Galderma her strong financial acumen and expertise in managing global corporations

ZUG, Switzerland, December 07, 2021--(BUSINESS WIRE)--Galderma, the world’s largest independent dermatology company, announced today that Maria Teresa "Tessa" Hilado will join its Advisory Committee, effective January 1, 2022.

Ms. Hilado currently serves on the board of directors at Campbell Soup Company, Zimmer Biomet Holdings, Inc. and Pharmaceutical Product Development, LLC.

"I look forward to working with Tessa Hilado as we
move forward with Galderma’s next growth phase.
Her appointment will greatly strengthen the Advisory Committee and shows our dedication to
increasing diversity at Galderma."

THOMAS EBELING
CHAIRMAN OF THE ADVISORY COMMITTEE, GALDERMA

A financial management specialist with over 30 years’ experience, Ms. Hilado brings a proven track record across several global corporations and brands. Her background includes pharmaceuticals, consumer products and industrials.

She most recently served as Executive Vice President and Chief Financial Officer at global pharmaceutical company Allergan PLC, from 2014 until her retirement in 2018. Prior to this, Ms. Hilado was Senior Vice President, Finance and Treasurer of PepsiCo Inc.; Vice President and Treasurer for Schering-Plough Corp.; and held several leadership roles at General Motors Company.

She holds a Bachelor of Science in Management Engineering from Ateneo de Manila University in the Philippines and an MBA from the University of Virginia Darden School of Business.

"I am thrilled to welcome Tessa to Galderma’s
Advisory Committee. Her vast expertise will be
instrumental in implementing our integrated
dermatology strategy and in fulfilling our ambition of
becoming the leading dermatology company in the
world."

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER, GALDERMA

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005498/en/

Contacts

Media contact

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting